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The development of therapeutic peptides and proteins is limited by the poor permeability and the selectivity of the cell membrane. The
discovery of protein transduction domains has given a new hope for administration of large proteins and peptides in vivo. We have developed a
non-covalent strategy for protein transduction based on an amphipathic peptide, Pep-1, that consists of a hydrophobic domain and a hydrophilic
lysine-rich domain. Pep-1 efficiently delivers a variety of fully biologically active peptides and proteins into cells, without the need for prior
chemical cross-linking or chemical modifications. The mechanism through which Pep-1 delivers active macromolecules does not involve the
endosomal pathway and the dissociation of the Pep-1/macromolecule particle occurs immediately after it crosses the cell membrane. Pep-1 has
been successfully applied to the screening of therapeutic peptides in vivo and presents several advantages: stability in physiological buffer, lack of
toxicity and of sensitivity to serum. In conclusion, Pep-1 technology could contribute significantly to the development of fundamental and
therapeutic applications and be an alternative to covalent protein transduction domain-based technologies.
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technology, an increasing interest is being taken in designing
novel strategies that allow the delivery of peptides and full-
length proteins into a large number of cells [1–5]. However, the
development of peptide-drugs and therapeutic proteins remains
limited by the poor permeability and the selectivity of the cell
membrane for large molecules. Recently, substantial progress
has been made in the development of cell-penetrating peptide-
based drug delivery systems which are able to overcome both
extracellular and intracellular limitations [1–7]. The cell
penetrating peptide (CPP) family includes several peptide
sequences: synthetic and natural cell-permeable peptides,
protein transduction domains (PTDs) and membrane-translo-
cating sequences, which are all capable of translocating the cell
membrane independently of transporters or specific receptors
[2]. A series of small peptides, termed protein transduction⁎ Corresponding author.
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doi:10.1016/j.bbamem.2006.02.006domains (PTDs), have been shown to cross biological
membranes efficiently, and to promote the delivery of peptides
and proteins into both cultured cells and animals [2,4–6].
Peptides derived from the trans-activating regulatory protein
(TAT) of human immunodeficiency virus (HIV) [8–11], the
third alpha-helix of Antennapedia homeodomain protein [2,12],
VP22 protein from herpes simplex virus [13], the poly-arginine
peptide sequence [14,15], peptide derived from calcitonin
[16,17] or from antimicrobial peptides Buforin I and SynB
[18,19] as well as Transportan and derivates [4,20] have been
successfully used to improve the delivery of covalently-linked
peptides or proteins into cells and have been shown to be of
considerable interest for protein therapeutics [1–5]. The use of
PTD-mediated transduction has proven that “protein therapy”
can have a major impact on the future of therapies in a variety of
viral diseases and cancers.
Protein transduction technology described so far requires the
attachment of the PTD to the target peptide or protein, which is
achieved by either chemical cross-linking or cloning and
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methods offer several advantages for in vivo applications
including rationalization, reproducibility of the procedure
together with the control of the stoichiometry of the PTD-
cargo. However, the covalent PTD technology is limited from
the chemical point of view, as it is mainly performed via a
synthetic disulfide linkage, and risks of alterating the biological
activity of the cargoes. In order to offer an alternative to the
covalent PTDs technology, we have designed a new strategy for
the delivery of full-length proteins and peptides into mamma-
lian cells, based on a short amphipathic peptide carrier, Pep-1.
This peptide carrier improves the delivery of several different
proteins and peptides in a fully biologically active form into a
variety of cell lines, without the need for prior chemical
covalent coupling or denaturation steps [23]. Pep-1 technology
constitutes a powerful tool for basic research and has been
demonstrated to be extremely powerful for studying the role of
proteins, and for targeting specific protein/protein interactions
in vitro as well as in vivo [23–29]. In this review article, we
describe the characteristics of the non-covalent Pep-1 strategy
and its applications for protein and peptide nucleic acid (PNA)
transduction both in vitro and in vivo. The internalization
mechanism of Pep-1 will be discussed on the basis of the
structural requirement for its cellular uptake.
1. Design and properties of Pep-1 peptide family
Pep-1 is a primary amphipathic peptide, of 21 residues,
(KETWWETWWTEWSQPKKKRKV) consisting of three
domains: a hydrophobic tryptophan rich motif (KETW-
WETWWTEW), required for efficient targeting to the cell
membrane and for forming hydrophobic interactions with
proteins, a hydrophilic lysine rich domain derived from the
Nuclear Localization Sequence (NLS) of SV40 large T antigen
(KKKRKV), required for the intracellular delivery and
solubility of the peptide vector, and a linker domain (SQP),
separating the two domains mentioned above, containing a
proline residue, which improves the flexibility and the integrity
of both the hydrophobic and the hydrophilic domains [23]. Pep-
1 sequence is acetylated at its N-terminus and carries a
cysteamide group at its C-terminus, both of which are essential
for the stability of the peptide and its transduction mechanism
[23,30]. The cysteamide function was introduced into several
peptide carriers [31,32] as its offers the advantage of being
compatible with Fmoc synthesis and avoids the use of
cysteine, thereby protecting its side chain [33]. Since Pep-1
was described in 2001, several modifications of Pep-1
sequences have been proposed in order to stabilize the cargo/
carrier complex or to extend the potency of this strategy to
other cargo molecules. Recently, we have designed a new
peptide carrier, Pep-2 (KETWFETWFTEWSQPKKKRKV),
which is able to interact with and facilitate the cellular uptake
of PNAs and derivatives such HypNA-pPNAs (trans-4-
hydroxyl-L-proline/phosphonate-PNA) [34]. The Pep-2 se-
quence differs from that of Pep-1 essentially by two Phe
residues at positions 5 and 9, which replace Trp residues in the
hydrophobic domain [34].Both Pep-1 and Pep-2 associate rapidly with cargoes in
solution through non-covalent hydrophobic interactions and
form stable complexes independently of a specific peptidyl
sequence [23–30]. Binding of cargoes to Pep-1 or Pep-2 can be
easily monitored by fluorescence spectroscopy using the Trp
residues located in the hydrophobic domain of the peptide, as a
sensitive sensor of the interaction (Fig. 1A). We have
demonstrated that both Pep-1 and Pep-2 exhibit a high affinity
for their cargoes, proteins or PNAs, in the nanomolar-range, and
form stable peptide-based nano-particles around the cargo, of a
size estimated between 100 and 200 nm diameter. The nano-
particles correspond to peptide/cargo ratios of about 10/1 to 15/
1 depending on the nature of the cargo (Fig. 1A and B). An
important criterion for a CPP is the balance between efficiency
and toxicity of the peptide, as most peptides, which interact with
membranes, are toxic to a certain extent. Evaluation of the
toxicity of Pep-1 and Pep-2 on different cell lines revealed that
both peptides do not exhibit any toxicity up to a concentration
of 100 μM, and 50% toxicity is reached for an average
concentration of peptides between 0.6 and 0.8 mM. Interest-
ingly, when Pep-carriers are associated to cargoes their toxicity
is reduced by 6-fold, with CC50 values between 3 and 5 mM
(Fig. 1C and D). This decrease in toxicity is associated with
particle structure stabilization, which involves the cysteamide
group, as already reported for other peptides used in the non-
covalent strategy [32,35].
2. Mechanism of internalization of Pep-1
Recently, the cellular uptake mechanism of PTDs has been
completely revised and shown to be essentially associated with
the endosomal pathway [36–40]. This was clearly demonstrated
for TAT-peptide; monitoring the cell entry of a biologically
active protein, the Cre-recombinase, has revealed a lipid-raft-
dependent macropinocytosis mechanism [40]. However, for
most CPPs, the cellular uptake mechanism still needs to be
confirmed, mainly due to the fact that very little is known
concerning the active conformation of CPPs associated with
membrane penetration and translocation [7,41]. There are
evidences for several routes of cellular uptake of CPPs, some
of which are independent of the endosomal pathway and
involve the trans-membrane potential [42,44,45]. When inves-
tigating uptake mechanisms of CPPs, several factors that may
affect their cellular uptake should be taken into account;
including the nature and structural constraints of the peptide, the
nature and size of the cargoes and cell types. Whichever the
CPP considered, the common major concern is to avoid the
endosomal pathway and/or to facilitate the escape of the cargoes
from the early endosomes to prevent their degradation. An
important criterion to be considered is the structural require-
ments for cellular uptake of CPPs. Only a few CPPs are able to
interact with the membrane lipids, and as clearly demonstrated
for Tat-PTD, the interaction with the cell surface occurs through
electrostatic contacts involving heparan sulfate at the surface of
the cells, without any conformational changes of the associated
PTD [7,41]. In contrast, Penetratin [3,44,45], Transportan [46]
or MPG [47,48] exhibit the ability to interact with membrane
Fig. 1. Formation and toxicity of Pep-1/cargo complexes. The binding of cargoes to Pep-1 and Pep-2 was monitored by fluorescence spectroscopy in phosphate buffer.
A fixed concentration of carrier (0.1 μM) was titrated by increasing concentration of cargoes. Panel A: Pep-1 was titrated with GFP-protein (red circle) and a 32-mer
peptide (blue circle) as previously described [23]. Panel B: Pep-2 was titrated with a short 15-mer HypNA-pPNA [34]. Intrinsic fluorescence of Pep-1 or Pep-2 is
centered at 340 nm upon excitation at 290 nm. The binding of cargo induced a quenching of intrinsic fluorescence of about 40% and dissociation constants were
estimated to 12±3 nM and 14±5 nM for Pep-1/GFP and Pep-1/peptide, respectively, and to 22±4 nM for Pep-2/ HypNA-pPNA. The toxicity of Pep-1 and Pep-2 was
investigated in different cell lines, including HeLa and Jurkat-T. Cells were incubated in the presence of increasing concentrations, from 0.1 μM to 1 mM of carrier
associated (panel D) or not (panel C) with a cargo molecule at a molar ratio of 20/1. The cell viability was estimated using MTT staining after 24-h incubation. Results
correspond to the average of 4 separate experiments and demonstrate that both carriers are not toxic on the cell lines tested, up to a concentration of 100 μM. The CC50
value was estimated to 0.5 mM for both peptides and is significantly increase upon association with the cargo molecule (CC50: 3 mM).
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interaction with lipids induces a folding of the peptide into a
helical or beta structure that controls its cellular uptake or
escape from early endosomes directly and therefore provides an
explanation for the difference in CPP uptake mechanisms
[7,41]. A variety of physical and spectroscopic approaches have
been combined to gain insight into the structure(s) involved and
to understand the interactions of Pep-1/cargo complexes with
lipids, and thus to characterize its mechanism of cellular
internalization. We have demonstrated that Pep-1 strongly
interacts with membrane lipids, mainly through its Trp-rich
domain, that was shown to be critical for insertion of the peptide
into the membrane. The direct interaction of the peptide with
lipids limits its association with proteoglycans at the surface of
the cell and the risk of uptake through the endosomal pathway
[30]. Interestingly, the conformation of Pep-1 is not signifi-
cantly affected upon formation of a particle with a peptide
cargo. In contrast, both NMR and circular dichroism analysis
have revealed that interaction of Pep-1 and Pep-1/cargo
complexes with phospholipids results in folding of the carrierinto an alpha helix [31]. We have suggested that the outer part of
the “Pep-1-based nanoparticle” with the cargo is involved in
interactions with the membrane and forms transient trans-
membrane helical structures that temporarily affect the cell
membrane organization, without associated leakage or toxicity,
thereby facilitating insertion into the membrane and initiation of
the translocation process. The presence of the cysteamide
group at the C-terminus of the peptide is essential for its
cellular uptake and probably favors either stabilization of the
particle and/or its interaction with lipids. Based on both
structural and biophysical investigations, a four-step mecha-
nism was proposed (Fig. 2): (a) formation of the Pep-1/cargo
complexes involving hydrophobic and electrostatic interac-
tions depending on the nature of the cargo, (b) interaction of
the complex with the external side of the cell involving
electrostatic contacts with the phospholipids head groups (c)
insertion of the complex into the membrane, associated with
conformational changes which induce membrane structure
perturbation (d) release of the complex into the cytoplasm
with partial “de-caging” of the cargo [31]. Although, the
Fig. 2. Mechanism of cellular uptake of Pep-1 based on the structure and biophysical characterization. A four step models: (1) formation of the Pep-1/cargo complexes,
(2) interaction of the complex with the external side of the cell involving electrostatic contacts with the phospholipids head groups (3) insertion of the complex into the
membrane, associated with conformational changes inducing membrane structure perturbation (4) release of the complex into the cytoplasm followed by “de-caging”
of the cargo.
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was clearly demonstrated that “decaging” occurs rapidly in the
cytoplasm, a few minutes after cellular uptake and that Pep-1
localizes in the nucleus irrespective of the nature of the cargo.
This can be directly correlated to the fact that particle
“undressing” is initiated in the membrane as a fraction of Pep-
1 molecules remain associated to the membrane. Moreover,
the kinetics of “decaging” are dependent on the nature of the
cargo, on its affinity for the target and on the subcellular
localization of the target.
3. Application of Pep-1 strategy to macromolecule
transduction
3.1. Pep-1-mediated transduction of peptides and large
proteins
Pep-1 technology has been applied to both basic researches
as well as to delivery of therapeutic peptides and proteins into
plants and mammalian cell lines (Table 1). Pep-1 has been
largely used for protein and peptide transduction, with high
efficiency (60 to 80%), into a large number of mammalian cell
lines, including non-transformed, cancer, neuronal and
primary cell lines [21,49]. This carrier promotes the cellular
uptake of small peptides and of large proteins, independently
of the size and the nature of the polypeptide and of the cell
types [23,24,28–30,49,50]. It has been shown to deliver
antibodies into cells, whilst preserving their ability to
recognize their target antigens, which constitutes a major
interest for therapeutic application. The lack of influence of
Pep-1 on the sub-cellular localization of the proteins it
delivers supports the fact that the “de-caging” process namelythe dissociation between Pep-1 and cargo occurs rapidly in the
cytoplasm once the complexes enter the cells (Table 1).
Improving the uptake of proteins and peptides into primary
cell lines remains an essential challenge; several protocols
have been described for the application of Pep-1 onto different
primary cell lines including macrophages [51], hepatocytes
[52], neural retinal [53], human stem [54] and pancreatic cells
[55]. Gallo and colleagues have optimized Pep-1 protocol for
peptides and proteins transduction into primary neuronal cells
[25,50,56].
3.2. Mechanism of cellular uptake of Pep-1/cargo complex
Artifacts can be associated with fixation methods as
described by several groups [36,37], but also with the use of
fluorescent probes attached to the CPPs, that can modify their
cellular behavior. Therefore, an essential rule when investi-
gating the uptake mechanism is to correlate the uptake
pathway with a biological response associated with the cargo
[40]. As several routes may exist, it is essential to identify the
one resulting in a biological response. A model experiment
based on the ability of Pep-1 to improve the delivery of the
cell cycle inhibitor protein p27Kip1 was performed to
understand its uptake mechanism. The cell cycle inhibitor
p27Kip1 binds to and inhibits Cdk/cyclin complexes involved
in the G1/S transition such as Cdk2/cyclin E and Cdk2/cyclin
A [57]. Due to its important role in the control of the cell
cycle progression, p27kip1 has been proposed to be a good
candidate for arresting cancer cell proliferation. A covalent
strategy based on a PTD-peptide has been successfully used
for the delivery of p27kip1 or derived inhibitory peptides into
cultured cells and ex vivo [22,58,59]. Pep-1 can efficiently
Fig. 3. Cellular uptake mechanism of the active form of Pep-1/cargo complex.
The cell cycle inhibitory protein 27kip1 (1 μM / 2μM) was formulated with Pep-1
at a molar ratio 1/20, in phosphate buffer. Human fibroblast HS-68 cells were
first synchronized by serum deprivation for 40 h, and then restimulated to enter
the cycle by addition of fresh medium supplemented with 20% FCS for 4 h and
overlaid with preformed Pep1/p27kip1 complexes. Cells treated with Pep-1 or
p27kip1 (panel A) or with Pep-1/p27kip1 (panel B) were analyzed by flow
cytometry 10, 15 and 20 h after release from synchrony. Panel C: Experiments
were performed in the absence (Mock) or presence of Cytochalasine D (10 μM),
Nystatin (50 μg/ml), Amiloride (5 mM) and Sodium Azide (0.1%). Cells were
incubated in the presence of the inhibitor 1 h prior addition of Pep-1/p27kip1
complexes and inhibitors were maintained for 1 h after transfection. After 1 h
were then treated with trypsin and resuspended in fresh medium. The level of
cell arrested in G1 was analyzed by flow cytometry, 24 h after release.
Table 1
Pep-1 mediated transduction of proteins and peptides
Cell lines Macromolecules References
3T3/L1-mouse fibroblast Antibody, Protein, Peptide [74]








Protein, Peptide, PNA [23,24]
PC-12 rat pheochromocytoma Protein, peptide [76,84]
A549 human lung carcinoma Antibody [29]
CV-1 monkey kidney Antibody [79]




COS-7 monkey kidney Protein, oligopeptide [23,24,75]














Primary human monocyte Protein [81]
Primary mouse hepatocytes Protein, PNA [52,66]
Primary rate type II alveolar
epithelial
Protein [27]
Primary chicken neural retina
cells
Protein [53]







Primary neurons Antibody, protein, peptide [25,50,77,87]
Bovine and monkey zygote Protein, antibody [70,71]
A non-exhaustive list of the application of Pep-1 strategy.
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transformed and cancer cells without the need for cross-
linking, which result in a cell cycle arrest in G1 in more than
70% of the cells (Fig. 3A and B). The p27kip1-associated
response was used to investigate the uptake mechanism of
Pep-1/cargo particles in cellulo. Uptake experiments were
performed in the presence of several inhibitors of the
endosomal pathway including Nystatin, Cytochalasin D, and
Amiloride, as well as NaN2 for energy depletion (Fig. 3C).
Results demonstrated that none of the inhibitors affected the
efficiency of Pep-1, with the exception of energy deprivation,
which reduced by 50% the biological response associated to
Pep-1-mediated p27kip1 delivery. This result can be directly
correlated to modification of membrane potential, known to
be required for uptake of CPPs [43]. We therefore proposed
that the uptake of the Pep-1/cargo complex leading to the
biological response is independent of the endosomal pathway
and is directly correlated to the size of particles and the nature
of cargoes.3.3. Pep-1 mediated transduction of biologically active
molecules
Pep-1 strategy has been successfully applied to introduce a
large variety of proteins, antibodies and peptides into different
cells lines (Fig. 4A–C). This strategy has been extended to the
delivery of other uncharged and charged cargoes, including
siRNA [60], DNA–protein complexes [23], replication-defi-
cient viruses [61], PNAs [34] and semiconductor quantum dots
[62]. PNAs have been proposed as an attractive alternative to
classical antisense oligonucleotides and efficient delivery using
covalent PTD-based strategies [21,63,64]. Pep-2 technology
has been used to significantly improve the delivery of both
uncharged PNAs and derivatives such HypNA-pPNAs (trans-4-
hydroxyl-L-proline/phosphonate-PNA) [65] into several cell
lines, this technology has been applied to target essential protein
in different cellular pathways [34,66]. We have proven Pep-2
Fig. 4. Pep-1 mediated delivery of macromolecules into mammalian cells. A concentration of 0.1 μM (0.7 μg) of FITC-labeled monoclonal anti-β-actin (panel A) or
51-mer peptides (0.1 μg) (panel B) was associated with Pep-1 at molar ratio 20/1. A concentration of 0.1 μM of FITC-labeled PNA (Panel C) was associated with Pep-
2 at a molar ratio 10/1. Cells were incubated with complexes for 1 h and then extensively washed prior to observation by confocal microscopy. Pep-2-mediated delivery
of PNA andHypNA-pPNA inhibits cyclin B1 expression. Increasing concentrations of HypNA-pPNAwere incubatedwith Pep-2 at amolar ratio of 1:25 at 37 °C for 1 h,
then overlaid onto cultured cells, as previously described [34]. Cyclin B1 protein levels were analyzed byWestern blotting after 24 h. Cdk2 protein was used as a control
to normalize protein levels (panel D). Panel E: Concentration-dependent Pep-1 and Pep-2 mediated cellular delivery of protein and PNA analogs. Fixed concentrations
of p27kip1 (0.5 μM/1 μg) and of an antisense HypNA-pPNA targeting Cyclin B1 (0.1 μM/0.2 μg) were associated with either Pep-1 or Pep-2, at different molar ratios
(from 1/1 to 50/1). The complexes were overlaid onto cultured HS-68 cells and the biological response being, either the level of G1-arrested cells induced by p27kip1 or
the decrease in Cyclin B1 protein levels associated to antisense HypNA-pPNA, was monitored 24 h after transduction.
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cyclin B1 protein (Fig. 4D), and efficiently block cancer cell
proliferation at very low concentrations of an antisense HypNA-
pPNA designed to target cyclin B1 [34]. We were able to reduce
both the doses and the time required for them to induce a
specific and robust biological response significantly, thereby
limiting non-specific cytotoxic effects described upon treatment
with high concentrations of PNAs.
Pep-1 and Pep-2 are manufactured under the name of
Chariot™ I and II by Active Motif inc. (http://www.activemotif.
com) and an update of the published work on the Chariot
strategy is available on the website of the company. Pep-1
protocols have been optimized according to the cell type or the
nature of the cargo and important parameters that need to be
taken into account have been defined; including reagent
concentration, cell confluence, toxicity of the cargo and
exposure time of cells to the Pep1/macromolecule complexes
[24]. The formation of Pep-1/Protein complexes is a critical step
which is directly associated to the ratio of Pep-1/cargo and to the
particle and therefore to the cellular uptake mechanism. As a
general rule, this ratio should be maintained between 15/1 and
20/1 to avoid aggregation/precipitation and to obtain an optimal
associated biological response (Fig. 4E). However, the nature
and size of specific cargo may affect the stability of the Pep-1/
cargoes particle and/or its dissociation within the cell. As Pep-1establishes mainly hydrophobic interactions with cargoes,
complex assembly depends on the structure, hydrophobic
pattern and biophysical properties of both components and
complex formation can therefore vary between different
combinations of Pep-1 and macromolecules [23]. Moreover, a
large implication of the electrostatic domain of Pep-1, which is
required for cellular uptake, in the interaction with the cargo
may reduce its efficiency. Finally, the size of the protein or
peptide may also affect the “decaging” step, and low efficiency
may be observed for mainly electrostatic peptides shorter than
15 residues [23,24].
3.4. Pep-1 mediated PNA and protein transduction in vivo
Several Pep-1-based formulations for in vivo applications
have been described including intra-venous, intra-tumoral,
intra-tracheal injections as well as transduction into oocytes or
sprays for skin or nasal delivery, suggesting that Pep-1
technology can be a potent technology for the delivery of
therapeutic proteins in vivo [27,29,67–69]. Interestingly, Pep-1
has be shown to be an excellent technology for protein and
antibody transduction in primary neurons and to be able to cross
the blood–brain barrier [26,50], as already reported for several
other CPPs [3,11]. Recently Pep-1 strategy has been applied in
vivo to the delivery of caspase 3 into the lung of mice to
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step in a cellular signaling pathway in vivo. Maron et al. [29]
have used Pep-1 for the delivery of PKA into distal lung
epithelial cells of rat in order to correct the defect in that protein
kinase. Pep-1 strategy was also applied for the evaluation of the
antitumoral activity of peptide inhibitors of protein kinase or of
antisense PNAs targeting cyclin B1, via intratumoral injections
[68,69] as well as for the delivery of antibodies and protein into
immature bovine and mouse oocytes, which offers a potent tool
for studying early embryonic development [70,71].
4. Conclusions
Over the past 10 years, substantial progress has been made in
the design of new technologies to improve cellular uptake of
therapeutic compounds [1–5]. This evolution is directly
correlated with the dramatic acceleration in the production of
new therapeutic molecules, whilst cell delivery systems
described until then were restricted by very specific issues.
CPPs constitute one of the most promising generations of tools
for delivering biologically active molecules into cells and can
thereby have a major impact on future of treatments [1–7]. They
have been shown to efficiently introduce drugs, antisense
DNAs, PNAs, oligonucleotides and small proteins into cells
both in vitro and in vivo. Peptide carriers present several
advantages, in that they are modulatable, lack immunogenicity,
are easy to produce and can incorporate a number of specific
attributes required for efficient cargo delivery and for
controlling their cellular behavior. Moreover, in addition to
their usefulness in the laboratory, they are promising reagents
for therapeutic applications [1–7].
Most of the CPPs described so far need a cross-linking step for
delivery of the protein, which may be a limitation to their
applications. In order to offer an alternative to covalent strategies,
we have proposed a new potent strategy for the delivery of full-
length proteins, peptides and PNAs into mammalian cells, based
on a short amphipathic peptide carrier, Pep-1, which can form
stable nano-particles with cargoes without the need for cross-
linking or chemical modifications [23]. Large varieties of
proteins, antibodies and peptides have been successfully
introduced into different cell lines using Pep-1 strategy and
have been shown to retain their full biological activity (Table 1).
Pep-1 technology has been successfully applied to the delivery of
different cargoes (PNAs, peptides and proteins) in different
animal models [27,29,67–72]. This peptide-based protein
delivery strategy presents several advantages including rapid
delivery of proteins into cells with very high efficiency, stability
in physiological buffers, lack of toxicity and lack of sensitivity to
serum. The lack of prerequisite for covalent coupling to
formation of Pep-1/macromolecule particles favors rapid release
of peptides or proteins into the cytoplasm as soon as the cell
membrane has been crossed. The final localization of the
delivered macromolecule is then determined by its inherent
intracellular targeting properties [23,24].
A major concern with the cellular uptake of CPPs is to
avoid the endosomal pathway or to favor escape of the cargo
from early endosomes. To this aim a domain-based strategywas recently proposed for the Tat-peptide, which combines the
PTD sequence with a membranolytic peptide sequence, the
HA2 fusogenic peptide of influenza to improve the release
from the endosomes [40,72]. Pep-1 behaves significantly
differently from other similarly designed cell-penetrating
peptides. Although we cannot exclude that Pep-1 uptake
follows several routes, the major Pep-1 cell translocation
mechanism is independent of the endosomal pathway and
involves transient membrane disorganization associated with
folding of Pep-1 into a helical structure within the phospho-
lipids membrane. Given that the mechanism through which
Pep-1 delivers macromolecules does not involve the endoso-
mal pathway, the degradation of macromolecules delivered is
significantly limited and rapid dissociation of the Pep-1/
macromolecule particle is favored as soon as it has crossed the
cell membrane.
In conclusion, although, it is clear than Pep-1 technology is
still in its early days and needs to be optimized for systematic in
vivo applications, it is already a powerful tool for basic research,
for studying the role of proteins and for targeting specific
protein/protein interactions in vitro and in vivo, as well as in a
therapeutic context for screening potential therapeutic proteins
and peptides. We believe that Pep-1 technology constitutes a
great alternative to covalent strategies and can have a major
impact on the use of proteins and peptides for future therapies.
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